SEMAGLUTIDE- REVOLUTIONARY DRUG IN OBESITY MANAGEMENT
Abstract
Semaglutide is one of the most widely used glucagon-like peptide-1 receptor agonists, initially approved for the treatment of type 2 diabetes and now increasingly utilized for obesity treatment. Its efficacy in weight reduction has led to a surge in popularity; however, concerns regarding its safety profile and potential side effects have emerged. This review aims to analyze the mechanism of action, therapeutic efficacy, and potential risks associated with semaglutide use.
References
Gundapaneni S, Burri R, Kaku R, et al. (February 05, 2025) Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes. Cureus 17(2): e78555. DOI 10.7759/cureus.78555
Mahapatra, M.K., Karuppasamy, M. & Sahoo, B.M. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord 23, 521–539 (2022). https://doi.org/10.1007/s11154-021-09699-1
Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. EndocrPract 2016;22:Suppl 3:1-203.
Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts 2015;8:402-424.
Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol 2018;6:237-248.
Neeland IJ, Poirier P, Després J-P. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation 2018;137:1391-1406.
Mahapatra, M.K., Karuppasamy, M. & Sahoo, B.M. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. Pharm Res 39, 1233–1248 (2022). https://doi.org/10.1007/s11095-022-03302-1
Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol (2012) 8:728–42. doi: 10.1038/nrendo.2012.140
Nauck MA, Meier JJ. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol (2019) 181:R211–34. doi: 10.1530/EJE-19-0566
DeFronzo RA, Triplitt CL, Abdul-Ghani M, Cersosimo E. Novel agents for the treatment of type 2 diabetes. Diabetes Spectr (2014) 27:100–12. doi: 10.2337/diaspect.27.2.100
Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes. Diabetes Ther (2019) 10:5–19. doi: 10.1007/s13300-018-0535-9
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
Ryan, D.H., Lingvay, I., Deanfield, J. et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med 30, 2049–2057 (2024). https://doi.org/10.1038/s41591-024-02996-7
Cornier MA, Després JP, Davis N, Grossniklaus DA, Klein S, Lamarche B, Lopez-Jimenez F, Rao G, St-Onge MP, Towfighi A, Poirier P; American Heart Association Obesity Committee of the Council on Nutrition; Physical Activity and Metabolism; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing, Council on Epidemiology and Prevention; Council on the Kidney in Cardiovascular Disease, and Stroke Council. Assessing adiposity: a scientific statement from the American Heart Association. Circulation. 2011 Nov 1;124(18):1996-2019. 11.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224. PMID: 33755728; PMCID: PMC7988425.
Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619. PMID: 35015037; PMCID: PMC8753508.
Feier CVI, Vonica RC, Faur AM, Streinu DR, Muntean C. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. Int J Mol Sci. 2024 Apr 15;25(8):4346. doi: 10.3390/ijms25084346. PMID: 38673931; PMCID: PMC11050669.
Ryan N, Savulescu J. The Ethics of Ozempic and Wegovy. J Med Ethics. 2025 Jan 23:jme-2024-110374. doi: 10.1136/jme-2024-110374. Epub ahead of print. PMID: 39848681.
Views:
66
Downloads:
19
Copyright (c) 2025 Gabriela Majka, Karol Bednarz, Piotr Pitrus, Anita Krowiak, Magdalena Kowalczyk, Karolina Krowiak, Aleksandra Karnas, Anita Warzocha, Wiktoria Hander, Maria Jasiewicz
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
